Sanofi raises 2026 guidance after strong Q2 performance
Pharmaceutical company Sanofi raised its 2026 financial outlook on July 30, 2026, following a second quarter that saw double-digit sales growth and robust business earnings per share (EPS).
Paris – Pharmaceutical company Sanofi announced on July 30, 2026, that it is upgrading its financial guidance for 2026. The company reported second-quarter sales growth of 17.8% in constant exchange rates (CER) and business earnings per share (EPS) of €2.09.
Sales from pharmaceutical launches increased by 48.3% to €1.3 billion, primarily driven by its products Ayvakit, ALTUVIIIO, and Sarclisa. Dupixent's sales rose by 37.6% to €5.2 billion, surpassing €5 billion per quarter for the first time.
Despite overall sales growth, vaccine sales decreased by 4.7% to €1.1 billion, a decline attributed to a high comparison base from influenza vaccines in the prior year. Research and development expenses increased by 17.9% to €2.2 billion, partly due to costs associated with pipeline prioritization.
The company also provided pipeline updates, including seven regulatory approvals across various therapeutic areas and two positive Phase 3 study readouts. However, Sanofi decided not to proceed with the global regulatory submission for amlitelimab and discontinued clinical development programs for itepekimab and balinatunfib.
With the revised guidance, Sanofi now expects sales to grow by approximately 10% at CER in 2026, with business EPS anticipated to grow slightly faster than sales. The company also completed a €1 billion share buyback program.